Breast

Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

(Morningstar) May 16, 2018 - Jounce Therapeutics, Inc. today announced that data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be the subject of an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5, 2018.

read article

Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects

(NPR/Shots Blog) May 16, 2018 - Sometimes less may be better when it comes to treatment for breast cancer. A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six months of treatment with the drug Herceptin (trastuzumab) as did women who received a 12-month course of this treatment.

read article

Shorter Drug Treatment Ok For Many Breast Cancer Patients

(NBCNews.com/Associated Press) May 16, 2018 - Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it sometimes can cause, a study suggests.

read article

Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting

(Array) May 16, 2018 - Array BioPharma Inc. announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in advanced BRAF-mutant melanoma in an oral presentation on June 4, 2018, at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

read corporate press release

GRAIL to Present New Data from Circulating Cell-free Genome Atlas (CCGA) Study at 2018 American Society of Clinical Oncology Annual Meeting

(Morningstar) May 16, 2018 - Results show prototype assays detected high mortality cancer types at early stages.

read article

New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting

(Merck) May 16, 2018 - Merck, known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from Merck’s oncology portfolio, anchored by anti-PD-1 therapy KEYTRUDA, will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. More than 140 abstracts in over 25 tumor types have been accepted, including new and long-term data for KEYTRUDA across multiple types of cancer.

read corporate press release

Multigene Testing Replacing BRCA Tests For Breast Cancer Risk

(Stanford Medicine) May 10, 2018 - Tests to detect mutations in multiple genes are replacing BRCA-only analyses in women with breast cancer, according to a study by scientists at Stanford and several other institutions. Greater access to genetic counselors needed.

read press release

Former Biotech Darlings Tesaro, Clovis Pin Hopes on 2018 Rebound

(Bloomberg) May 10, 2018 - In June, Tesaro is expected to issue more results from a mid-stage study of Zejula and Merck & Co.’s Keytruda in ovarian and breast cancer.

read article

Fending Off Lymphedema Through Early Intervention

(University of Kansas) May 7, 2018 - A study conducted by researchers at The University of Kansas Cancer Center has found that early, ongoing screening of lymphatic function and immediate patient-administered therapies are highly effective in improving outcomes for women at high risk for breast cancer related lymphedema.

read article

Bayer Highlights Latest Oncology Research at ASCO 2018

(Bayer) May 17, 2018 - Clinical research to be presented from Bayer's growing oncology portfolio, including radium Ra 223 dichloride, sorafenib, regorafenib, copanlisib and other pipeline compounds.

read corporate press release

Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care

(Lilly) May 16, 2018 - First presentation of findings from the ramucirumab REACH-2 study - the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population; Research across the MONARCH clinical development program reinforcing the benefit of abemaciclib in advanced breast cancer will also be presented.

read corporate press release

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration

(NASDAQ) May 21, 2018 - First-in-class antibody-drug conjugate had received prior breakthrough therapy designation from the FDA for the treatment of metastatic triple-negative breast cancer.

read article

Association of Community Cancer Centers and Pfizer Offer Grant Opportunities Focused on Improving Quality of Breast Cancer Care Through Evidence-Based BRCA Genetic Testing

(ACCC) May 21, 2018 - To support quality improvement (QI) projects in breast cancer, the Association of Community Cancer Centers (ACCC) has joined with Pfizer Independent Grants for Learning and Change (IGLC) to issue a Request for Proposals (RFP) with the intent of funding QI initiatives that fully integrate BRCA testing into patient care plans in order to help inform the treatment decision-making process.

read press release

Bladder Cancer Model Could Pave The Way For Better Drug Efficacy Studies

(UNC Lineberger) May 21, 2018 - Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients respond to new immune-based treatments.

read article

Opinion: Congress — When Considering Women’s Health, Don’t Forget About Lung Cancer

(The Hill) May 19, 2018 - National Women’s Health Week is an opportunity to shine a light on a women’s health imperative that will take the lives of more women this year than breast, ovarian, cervical and uterine cancers – combined, yet still exists on the fringes of the public consciousness.

read article

Particle Shows Promise To Prevent The Spread Of Triple-Negative Breast Cancer

(USC News) May 18, 2018 - Like a smart bomb, the potential treatment delivers a cancer-fighting drug directly to cells, deterring metastasis to the lungs.

read article

Novartis Data at ASCO and EHA Reinforce Company's Commitment To Reimagining Cancer

(Novartis) May 17, 2018 - Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be presented at ASCO; Long-term analyses of Tasigna® Treatment-free Remission (TFR) studies in Ph+ CML-CP to be featured at both congresses; New 12-month updates from JULIET trial of Kymriah® in relapsed/refractory DLBCL to be presented at EHA.

read corporate press release

Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018

(BMS) May 16, 2018 - First analysis from Phase 3 CheckMate -227 Part 1b in first-line non-small cell lung cancer, assessing Opdivo plus chemotherapy and Opdivo plus Yervoy versus chemotherapy in patients with PD-L1 <1%; Updated data from Phase 3 CheckMate -238 study of Opdivo as adjuvant treatment in Stage III/IV melanoma will further explore potential durability of recurrence-free survival; Seven BMS compounds to be featured in presentations spanning more than 20 types of cancer.

read corporate press release

Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

(Nektar) May 16, 2018 - Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer.

read corporate press release

What's Hot (and Overheated?) at ASCO 2018

(Medscape Medical News) May 21, 2018 - The largest cancer meeting in the world is coming up soon, with 39,000 attendees descending on Chicago on June 1 for the annual meeting of the American Society of Clinical Oncology (ASCO).

read article (free registration required)
Next Page